IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.940
+0.030 (1.57%)
At close: Mar 13, 2026, 4:00 PM EDT
1.880
-0.060 (-3.09%)
After-hours: Mar 13, 2026, 7:37 PM EDT
IN8bio Market Cap
IN8bio has a market cap or net worth of $18.61 million as of March 13, 2026. Its market cap has increased by 1.33% in one year.
Market Cap
18.61M
Enterprise Value
-5.70M
1-Year Change
1.33%
Ranking
Category
Stock Price
$1.94
Market Cap Chart
Since the IPO on July 30, 2021, IN8bio's market cap has decreased from $187.55M to $18.61M, a decrease of -90.08%. That is a compound annual growth rate of -39.34%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 18.46M | 86.99% |
| Dec 31, 2025 | 9.87M | -47.05% |
| Dec 31, 2024 | 18.64M | -68.76% |
| Dec 29, 2023 | 59.67M | 5.43% |
| Dec 30, 2022 | 56.60M | -31.25% |
| Dec 31, 2021 | 82.33M | -56.10% |
| Jul 30, 2021 | 187.55M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Longeveron | 20.77M |
| Daré Bioscience | 20.43M |
| Allarity Therapeutics | 20.26M |
| VYNE Therapeutics | 19.70M |
| Pasithea Therapeutics | 18.93M |
| Lixte Biotechnology Holdings | 17.74M |
| Lexaria Bioscience | 17.42M |
| Cadrenal Therapeutics | 17.30M |